A Multiplexed Serum Biomarker Immunoassay Panel Discriminates Clinical Lung Cancer Patients from High-Risk Individuals Found to be Cancer-Free by CT Screening
Open Access
- 1 April 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 7 (4), 698-708
- https://doi.org/10.1097/jto.0b013e31824ab6b0
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor ModelsCancer Cell, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung CancerJNCI Journal of the National Cancer Institute, 2011
- Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomicsMuscle & Nerve, 2010
- Reproducibility of serum cytokines and growth factorsCytokine, 2009
- Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer SeraJournal of Clinical Oncology, 2008
- The Pittsburgh Lung Screening Study (PLuSS)American Journal of Respiratory and Critical Care Medicine, 2008
- Association of Radiographic Emphysema and Airflow Obstruction with Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancerBritish Journal of Cancer, 2004
- Early Lung Cancer Action Project: overall design and findings from baseline screeningThe Lancet, 1999